Can a Two-Drug combo keep CLL at bay for years? a 10-Year watch begins
Knowledge-focused
Recruiting now
This study follows people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who previously received a combination of ibrutinib and venetoclax in the CAPTIVATE trial. Researchers will track their health for up to 10 years to see what treatments they need …
Sponsor: European Research Initiative on CLL • Aim: Knowledge-focused
Last updated Aug 20, 2026 10:00 UTC